We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$810M
AUM Growth
+$268M
Cap. Flow
+$286M
Cap. Flow %
35.27%
Top 10 Hldgs %
71.5%
Holding
51
New
7
Increased
2
Reduced
11
Closed
1

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$185M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$36.1M
3
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$28.7M
4
RXRX icon
Recursion Pharmaceuticals
RXRX
+$23M
5
JANX icon
Janux Therapeutics
JANX
+$13.5M

Top Sells

Rank Stock Value
1
CVAC
CureVac
CVAC
+$8.72M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$5.19M
3
TERN
Terns Pharmaceuticals
TERN
+$3.55M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$2.71M
5
KRON
Kronos Bio
KRON
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 92.52%
2 Financials 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
26
Rhythm Pharmaceuticals
RYTM
$7.72B
$5.88M 0.73%
300,293
+99,247
+49% +$2.06M
TNGX icon
27
Tango Therapeutics
TNGX
$4.72B
$5.69M 0.7%
500,000
– –
JYAC
28
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.04M 0.62%
507,041
– –
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
$4.61M 0.57%
+202,500
New +$4.22M
EQ icon
30
Equillium
EQ
$134M
$4.35M 0.54%
738,176
-26,227
-3% -$165K
EYPT icon
31
EyePoint Inc
EYPT
$1.08B
$4.05M 0.5%
450,000
– –
AVDL
32
DELISTED
Avadel Pharmaceuticals
AVDL
$3.7M 0.46%
549,250
– –
TERN
33
DELISTED
Terns Pharmaceuticals
TERN
$3.54M 0.44%
289,068
-208,487
-42% -$3.55M
ALBO
34
DELISTED
Albireo Pharma Inc
ALBO
$3.52M 0.43%
100,000
– –
BCEL
35
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.38M 0.42%
396,835
– –
KALA icon
36
KALA BIO
KALA
$14.2M
$3.19M 0.39%
241
– –
BLSA
37
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.16M 0.39%
300,000
– –
CHFW.U
38
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$3.12M 0.39%
300,000
– –
IMCR icon
39
Immunocore
IMCR
$1.75B
$2.5M 0.31%
64,000
-16,000
-20% -$618K
ALPN
40
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.48M 0.31%
275,169
-124,021
-31% -$1.35M
ODT
41
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.44M 0.3%
700,421
– –
VTGN icon
42
VistaGen Therapeutics
VTGN
$12.6M
$2.31M 0.28%
24,420
-36,630
-60% -$2.71M
SNCE
43
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2M 0.25%
10,000
– –
KRON
44
DELISTED
Kronos Bio
KRON
$1.87M 0.23%
78,131
-88,119
-53% -$2.23M
RCKT icon
45
Rocket Pharmaceuticals
RCKT
$387M
$1.8M 0.22%
40,550
-23,220
-36% -$1.01M
KLRS
46
Kalaris Therapeutics
KLRS
$99.7M
$1.63M 0.2%
3,580
– –
BNTX icon
47
BioNTech
BNTX
$22.9B
$1.29M 0.16%
5,758
-5,037
-47% -$950K
NGM
48
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$359K 0.04%
18,225
– –
ATXS
49
DELISTED
Astria Therapeutics
ATXS
$317K 0.04%
25,000
– –
AMRN
50
Amarin Corp
AMRN
$301M
$110K 0.01%
1,250
– –
1
2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q2 2021 Portfolio in Review

As of Q2 2021, Samsara BioCapital held 51 positions worth $810M, up 49% from $542M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Samsara BioCapital deployed $286M of net new capital in Q2 2021, opening 7 new positions and adding to 2 existing holdings. Its largest new stake was LENZ Therapeutics: 1,061,660 shares worth $228M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $5.19M trimmed.

  • Samsara BioCapital's largest Q2 2021 buy was LENZ Therapeutics: 1,061,660 shares worth $228M.
  • Samsara BioCapital added most to Instil Bio in Q2 2021, an estimated $11M increase.
  • Samsara BioCapital's biggest Q2 2021 reduction was Aclaris Therapeutics, cutting an estimated $5.19M.
  • Samsara BioCapital fully exited CureVac in Q2 2021, selling an estimated $8.72M.
  • Samsara BioCapital's ten largest holdings make up 72% of its $810M portfolio in Q2 2021.
  • Samsara BioCapital opened 7 new positions and closed 1 in Q2 2021.
  • Samsara BioCapital's portfolio value rose 49% quarter-over-quarter to $810M.

Based on Samsara BioCapital's 13F filing for Q2 2021, filed 17 Aug 2021.